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Abstract: We have developed a spectral inversion method for three-
dimensional tomography of far-red and near-infrared fluorescent proteins in 
animals. The method was developed in particular to address the steep light 
absorption transition of hemoglobin from the visible to the far-red occurring 
around 600 nm. Using an orthotopic mouse model of brain tumors 
expressing the red-shifted fluorescent protein mCherry, we demonstrate 
significant improvements in imaging accuracy over single-wavelength 
whole body reconstructions. Furthermore, we show an improvement in 
sensitivity of at least an order of magnitude over green fluorescent protein 
(GFP) for whole body imaging. We discuss how additional sensitivity gains 
are expected with the use of further red-shifted fluorescent proteins and we 
explain the differences and potential advantages of this approach over two-
dimensional planar imaging methods. 
©2011 Optical Society of America 
OCIS codes: (170.6960) Tomography; (170.3880) Medical and biological imaging. 
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1. Introduction 
Fluorescent proteins (FPs) have revolutionized biological discovery by allowing visualization 
of cellular and sub-cellular molecules, structures and processes [1,2]. The ability to image and 
quantitate such processes at the whole body level would enable functional ‘-omics’ and/or 
allow the detailed tracking of cell populations over time. As we move to systematically 
explore the function and regulation of protein networks - either normally functioning ones, 
alterations in disease or through therapeutic manipulation - it is increasingly important to 
visualize various events in situ in the appropriate organ and within complex living 
environments. In this role, the use of mammalian animal models has been invaluable to bridge 
the divide between in vitro research and the clinical application of therapeutic strategies. 
Intravital microscopy [3,4] has paved the way for the utilization of FPs in the 
understanding of cellular and sub-cellular function in vivo. The use of this technique, 
however, is significantly limited by the inability to non-invasively visualize activity deeper 
than a few hundred microns, for example from entire solid tumors, or within organs and 
systems. Epi-illumination imaging, which uses single projection imaging, has likewise been 
employed for imaging surface activity at depths of a few millimeters [5,6]. In this approach, 
the fluorescence intensity has a strong, non-linear dependence on both the depth of the activity 
and the underlying tissue optical properties. Consequently, this impedes the ability to 
accurately quantify the underlying fluorescence activity. Fluorescence tomography (FMT) [7], 
a model-based reconstruction method, has been developed as an alternative, quantitative, 
three-dimensional imaging technique to overcome the limitations of epi-illumination and to 
visualize the distribution of fluorescence probes in vivo. Through several technical 
developments recent systems utilize CCD cameras, which allow high spatial sampling of 
photon propagating through tissues at multiple projections, i.e. at multiple illumination 
detection paths [8] and wavelengths [9]. Fluorescence tomography has been previously shown 
to resolve GFP and dsRed reporter protein expression in-vivo [10–12], however limitations 
associated with operation in the visible spectrum (<600 nm) were noted, such long acquisition 
times and thus limitation to single view projections. 
The ability to resolve fluorescent reporter proteins operating in the near-infrared could 
significantly improve the applicability of these imaging techniques in the study of biological 
function. Seminal ongoing research on FP development has resulted in a variety of adept red-
shifted constructs that operate in the far-red (RFPs) [13–19], and recently, in the near-infrared 
(IFP) [20]. It has been predicted that the signals emitted from RFPs can be detected for several 
millimeters to centimeters in tissues [21], which would allow visualization through entire 
small animals, such as mice or rats. This feature is due to a peculiarity in the hemoglobin 
absorption spectrum that yields a steep drop in the extinction coefficient at wavelengths that 
are longer than 600-610 nm. As a result, light attenuation in tissues is significantly lower in 
the far-red and near-infrared (630 – 900 nm) compared to the visible. Yet, the excitation of 
most RFPs remains in the visible range (<630 nm), where light experiences strong 
attenuations when traveling through tissue [13,14,16]. This imposes several methodological 
difficulties on the development of strategies that can accurately illuminate, capture and 
reconstruct the fluorescence biodistribution of fluorochromes that operate at a highly varying 
attenuation background. 
For this reason, in the present study, we explored a method that can optimally reconstruct 
the three dimensional distribution of FP activity through the entire volume of a mouse. To 
achieve optimal performance, the imaging method developed herein incorporates optimum 
excitation and emission wavelengths, efficient tissue autofluorescence subtraction techniques, 
and forward light propagation models that work seamlessly at both sides of the steep light 
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normalized Born (n-Born) ratio and concurrently utilizes four-dimensional data sets (i.e., 
sources, detectors, angular projections, and emission wavelengths). We show that the forward 
and inversion components selected are necessary in order to achieve accurate fluorescence 
biodistribution reconstructions in deep tissue, over conventional FMT methods developed for 
the near-infrared. This approach, along with the longer light penetration in the red part of the 
spectrum, allowed the visualization of mCherry-labeled glioblastoma tumors in vivo achieving 
at least one order of magnitude increased sensitivity compared to volumetric imaging using 
GFP, with the potential to significantly further improve the sensitivity using novel classes of 
contrast agents. Herein, we present the major methodological steps, key in vivo results, and 
major cross-validation findings that showcase the necessity and superior performance 
achieved with this method, over near-infrared (NIR) optical tomography approaches and 
discuss the application potential of the approach for non-invasive imaging of RFPs in vivo. 
2. Materials and methods 
2.1. Tomographic system and data acquisition 
The small animal imaging system developed is shown in Fig. 1. It is highly versatile as it can 
be operated either in epi-illumination or transillumination mode, and can be used to image the 
animals both in free space (as a non-contact full-angular projection FMT system) [8], or by 
placing them in a chamber (single projection). The laser sources used in the imaging setup are 
a tunable Ar-ion laser (Melles Griot, Carlsbad, CA) at 488 and 514 nm (200 mW), a 532 nm 
100 mW NdYAG laser (B&W Tek Inc., Newark DE), a 593 70mW nm DPSS laser (Shanghai 
Dream Lasers, China), a 635 nm 3 mW diode laser (Roithner Lasertechnik GmbH, Vienna, 
Austria), and 650, 670, and 750 nm 200 mW diode lasers (B&W Tek Inc., Newark DE). No 
filters to clean up the laser beams were necessary. The lasers were fiber-coupled and guided 
through a multiport fiber switch (DiCon Fiberoptics, Inc, Richmont CA) into a two-mirror 
scanhead (XLR8, Nutfield Technology, Inc., Windham, NH). The beam was focused with a 
telecentric lens at a 0.3 mm spot onto the surface of the animal and scanned in x-y direction. 
The photon field emerging from the animal surface was imaged from the opposite side with a 
cooled 70°C CCD camera (Princeton Instruments, Inc. Trenton, NJ) with a Nikkor 50 mm 
f/1.2 photographic lens (Nikon Corp, Japan). For the image acquisition at various spectral 
bins, a series of 10 nm bandpass filters (Andover Corp., Salem, NH, and Chroma Technology 
Corp., Rockingham, VT) were used with central wavelengths at 514, 532, 593, 610, 620, 630, 
640, 650, 670, 710, 750, and 800 nm offering a rejection ratio of 6.0 OD at 20 nm away from 
the center wavelength. For the in vivo tomographic imaging experiments, the mice were 
suspended by their teeth using a snout clamp (Harvard Apparatus, Holliston, MA), mounted in 
a step rotating stage (Newport Corporation, Irvine, CA) and imaged in free space (Fig. 1). The 
system is enclosed in a black box and the temperature remained above 25° C during the free 
space one hour experiments. For the FP intensity and tissue autofluorescence measurements, 
 
 
Fig. 1. Schematic of the experimental tomographic system (in free-space configuration). 
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two parallel glass plates at 1.2 cm. Although not necessary, in these experiments the chamber 
was filled with matching fluid (Intralipid and ink) to help block the stray light coming from 
the sides of the mouse; the water temperature was kept ca. at 30° C. In order to keep the mice 
anesthetized, isoflurane-oxygen gas mixture (1%) was piped through a tube to the mouse 
snout. 
For the acquisition of the complete tomographic data set, the specimen was rotated at Np = 
19 different projections and for each projection it was scanned with a rectangular Ns = 3x5 
source pattern occupying a 3.8 × 7.6 mm
2, thus resulting a sequence of 285 images. This 
imaging procedure was repeated for every combination of fluorescence filters Nw = 5   
(610, 620, 630, 640, 650 nm) and illumination laserlines (593 nm for Ufl and 532 nm for Uau). 
In addition, it was repeated once with the 635 nm laserline and no filter to record an image Un 
to be used for the n-Born ratio calculation. Finally, the silhouettes of the object were captured 
against a white background at 72 different projections to render its 3D surface using a 
reconstruction algorithm based on a volume carving [22,23]. The whole imaging session 
lasted approximately 1 h where the camera exposure time (~1 s) was the most time consuming 
factor. Mice were kept under general anesthesia during placement and imaging with a 1% 
isoflurane-oxygen mixture. 
2.2. Tissue mimicking phantom 
A 16 mm diameter cylindrical phantom was produced from a melt prepared from 1% agar in 
water that was heated up to 95°C. In the cooling phase 1% Intralipid and 1% whole blood 
were added at 45°C. The phantom was cast in a cylindrical shape enclosing two 1 mm 
diameter tubes inside the phantom containing 60 and 15 pmol of TexasRed (Sigma-Aldrich). 
2.3. Lentivirus vectors and cell lines 
Lentivirus vectors encoding GFP (Clontech), or mCherry,(from Dr. R. Tsien, UCSD, CA), all 
under the control of the CMV promoter were constructed based on the lentivirus cloning 
vector CSCGW as described previously [24,25]. The viral vector titers (transducing units 
(TU)/ml) were determined by counting the number of fluorescent positive cells 48 h after 
infection. U87dEGFR human glioblastoma cells (ATCC) were transduced with 20 TU/cell of 
LV-GFP or LV-mCherry in order to produce U87dEGFR-GFP and U87dEGFR-mCherry 
cells. All transduced cells expressed the FPs and were cultured in DMEM supplemented with 
10% fetal calf serum and antibiotics. 
2.4. Fluorescent protein concentration in cells 
We have used an optical method to determine the concentration of FPs in cells by comparing 
the intensity of the emitted fluorescence with Texas Red fluorochrome of a known 
concentration. Two identical glass capillary tubes where filled with 0.2 μM of Texas Red and 
4 million of mCherry U87 cells that were centrifuged at 2000g for 5 min to form a dense 2 μL 
pellet and were imaged in the system (section 2.1) using the 593 nm laser and the 620 nm 
bandpass filter. Taking into account the molar extinction coefficients, the quantum yields and 
the spectral absorption and emission profiles [14,26] we have determined that the mCherry 
concentration in the pellet was approximately 18 μM, which accounts for 5 million copies of 
protein per cell. 
2.5. Mouse phantom 
A total of 10
6 U87dEGFR cells expressing the different FPs were placed into small glass 
capillary tubes of 0.9 mm inner diameter and centrifuged to create dense pellets. The relative 
brightness of the GPF to the mCherry cells was calculated from fluorescence epiillumination 
images and was found to be approximately 1/2.5, attributed to different expression levels. 
This mismatch was taken into account in the following calculations. The capillary tubes were 
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For these experiments, the mice (n = 2) were placed in the water-tight chamber and slightly 
compressed in the torso between two parallel glass plates at 1.2 cm. Although not necessary, 
the chamber was filled with matching fluid (Intralipid and ink) to help blocking the stray light 
coming from the sides of the mouse. The tube in the esophagus was 8 mm away from the 
dorsal side and 4 mm from the ventral side, and the mouse was imaged in transillumination 
twice, once for each direction (dorsal to ventral and ventral to dorsal), in order to have two 
different location geometries of the tube. The recorded signals were averaged along a region 
of interest around the illumination point and were normalized for the laser power, filter 
transmittance, camera integration time, and FP relative brightness. 
2.6. U87dEGFR-mCherry brain tumor model 
Animal studies were approved by the Massachusetts General Hospital Review Board. For 
experimental brain tumors, 4-5 week old nude mice (n = 10) were anesthetized with 
intraperitoneal injection of ketamine (100 mg/kg) and xylazine (5 mg/kg) and then mounted 
on a stereotaxic frame using a specially made mold to orient the head. The skin was cleaned 
by scrubbing with 70% ethanol pads, followed by scrubbing with betadine pads. The skull 
was exposed by a small incision. A small burr hole (<0.5 mm) was made using a high-speed 
drill at the appropriate stereotaxic coordinates for injection into the brain. Two μL containing 
2 x 10
5 U87dEGFR-mCherry cells were injected into the brain (3 mm lateral and 1.5 mm 
caudal to bregma; depth 1.5 and 3.5 mm from dura) with a 33 gauge Hamilton syringe. After 
closing the scalp the mice were placed on a warming pad and returned to cages after full 
recovery. The mice were imaged 7 days later. 
2.7. Autofluorescence subtraction and image pre-processing 
Initially, the background noise was subtracted from all images. In order to calibrate the 
images across the various wavelengths, a tube with the fluorochrome/FP has been placed in 
the field of view of the camera and was imaged in various wavelengths using the same filter 
settings as in the tomographic imaging experiments. The pixel values of the fluorescence 
images are proportional to the relative brightness of the FP, the filter transmittance, and the 
sensitivity of the camera for each wavelength used; these value were used to scale the raw 
images. In in vivo experiments, the autofluorescence images  au U  (excited by a shorter 
wavelength 532 nm) were appropriately scaled (by a factor a) and subtracted pixel-by-pixel 
from the corresponding fluorescence images  fl U  (excited at 593 nm) to yield an 
autofluorescence corrected image  fl au Ua U  . For each resulting image, a rectangular pattern 
of virtual detectors was obtained and which was projected to the object surface. For the 
phantom experiment, a 12x11 source pattern over a 13x10 mm
2 area was used. For the mice 
experiments, a narrower 7x11 pattern over a 7x11 mm
2 area was used, so as to avoid the high 
intensity areas at the edge of the mice. Both sources and detectors were virtually projected on 
the mouse surface as calculated from the silhouettes. The n-Born ratio  nB U  was calculated for 
each source detector pair using Eq. (1) and thus resulting a total of n = 34485 measurements 
for the phantom, and n = 21945 for the mouse imaging. 
2.8. Multispectral forward problem – reconstruction 
The volume of interest was discretized in a rectangular equidistant mesh for which the 
fluorescence concentration would be calculated. The size of the mesh in the cylindrical 
phantom was Nm = 26 × 17 × 26 = 11492 occupying 22 × 13 × 22 mm
3, while for the mouse it 
was Nm = 21 × 20 × 20 = 8400 occupying 20 × 13.3 × 19 mm
3. For every source-detector (s-d) 
combination, the contribution/weight of each mesh point m to the fluorescence intensity 
detected at d was calculated by modeling the photon propagation using the n-Born 
#139767 - $15.00 USD Received 16 Dec 2010; revised 1 Mar 2011; accepted 7 Mar 2011; published 16 Mar 2011
(C) 2011 OSA 1 April 2011 / Vol. 2,  No. 4 / BIOMEDICAL OPTICS EXPRESS  892approximation [7]. The normalized data  nB U  were connected with the unknown fluorophore 
concentration C with the linear equation 
 
() ( ) ( ) nm n m
nB UW C
     (1) 
where, m are the mesh points, n are the measurements, 
() mn W
  is the mn   weight matrix 
describing the contribution of each voxel to the signal measured at each detector, which is a 
function of the optical properties of the object. We used the diffusion approximation in the 
radiation transfer equation [27], where the diffuse photon density wave in an infinite medium 
at a distance r from a point source is described in terms of Green’s functions 
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where  sm r ,  md r , and  sd r  are the distances between source (s), mesh (m), and detector (d) 
points respectively, and  a
   and  s
  are the absorption and scattering coefficients at the 
excitation ( e  ), fluorescence ( f  ), and normalization ( n  ) wavelengths. Contrary to the 
formulation of the forward model in the NIR application, the Green’s functions modeling the 
light propagation were calculated: (a) at 593 nm for the source-mesh point pair (Gsm), (b) at 
either of the spectral bins of the emission for the mesh-detector pair (Gmd), and c) at 635 nm 
for the source-detector pair Gsd. The values of the optical coefficients used were a 
combination of those reported in various papers [28–31] and values not available for some 
wavelengths were projected or interpolated. For the head, 15 to 12 cm
1 was used for μs and 
0.8 to 0.2 cm
1 for μa in the 593 – 650 nm spectral range, and correspondingly for the phantom 
13.6 - 12.5 cm
1 for μs and 0.3 - 0.09 cm
1 for μa. 
In the reconstruction of the multispectral data set an extra dimension was added in Eq. (2) 
for the k spectral regions multispectral measurements: 
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The U vector has nk   elements, the weight matrix has mnk    elements, and the C vector 
has still m elements. Among the different spectral bands, the elements of the weight matrix 
share the same optical properties for the source-mesh and the source-detector Greens’ 
functions, but have different values for the mesh-detector pairs. 
The inversion of Eq. (2) is performed simultaneously with all the wavelengths using a 
random algebraic reconstruction technique (ART) after 50 iterations. ART was implemented 
in two ways: Firstly, the rows of each wavelength are separated into different classes and the 
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Secondly, all the rows were included in a single class which was accessed in random order. 
There was no significant difference in the results between the two approaches. Finally, an 
extra dimension was added to include the different projections, which was accessed in a 
sequential order outside the two access schemes described before. The total reconstruction 
time including the surface rendering is approximately 3 mins, in a Core 2 Duo system with 4 
GB RAM. A typical multispectral weight matrix calculation and inversion lasted 5-10 mins. 
2.9. MR imaging 
MRI was performed in a Bruker Pharmascan 4.7T scanner (Brucker Biosciences, Billerica, 
MA) with the mice (n = 3) being anesthetized with 1% isoflurane-oxygen mixture, and 
injecting 0.6 μmol/g gadopentetate dimeglumine (Gd-DTPA) contrast agent (Magnevist, 
Schering, Berlin, Germany) via tail vein injection [32]. A series of axial and coronal T1-
weighted and T2-weighted scans where acquired pre- and post-Gd-DTPA tail-vein injection, 
to verify the high uptake from the tumor. All scan sequences were acquired with 256x256 
resolution, 20 slices with a 0.6 mm slice thickness, and a 36x36 mm
2 and 25x25 mm
2 field of 
view for the axial and coronal scans, respectively. The number of images averaged (NEX) 
was 8. T1-weighted scan parameters were TR = 873 ms, TE = 18 ms, and in T2-weighted, TR 
= 3514 ms and TE = 63 ms. The total imaging time per mouse was 45 minutes. 
2.10. Implementation outline 
An outline of data processing and reconstruction scheme followed in the present study is 
schematically presented in Fig. 2. The tissue was scanned at 593 nm, which falls near the RFP 
peak excitation, and at 532 nm, which is distinct from the peak and excites mostly tissue 
autofluorescence. For both 593 and 532 nm excitation wavelengths, the fluorescence images 
were acquired at emission wavelengths in the 610-650 nm range and at multiple angular 
projections. The data collected with the 532 nm excitation were used to correct for the 
autofluorescence that is present in those data sets acquired with the 593 nm excitation. Images 
of the tissue transmission were acquired with a 635 nm laser line without a filter and were 
used to normalize for the non-uniform illumination and the variations of tissue optical 
properties. Similarly, light propagation was modeled for each source-detector pair, angular 
projections, and multiple excitation and emission wavelengths, to create a hyper-dimensional 
weight matrix, which was inverted to calculate the three dimensional (3D) distribution of the 
fluorescence concentration. 
 
Fig. 2. Outline of the algorithmic implementation. Multicolored boxes denote multispectral 
data acquisition and processing. 
3. Results and discussion 
3.1.  Tissue optical properties and performance of FPs 
The intensity of the detected fluorescence photons that are emanating from deep-tissue 
depends on the FP brightness and on the light attenuation at the excitation and emission 
wavelengths. For tissue that is 8 mm thick, the attenuation of light above 600 nm is two orders 
of magnitude less compared to 500 nm (Fig. 3(a)), signifying a considerable advantage for the 
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these FPs, 10
6 human glioblastoma cells stably expressing GFP (U87dEGFR-GFP), the RFP 
mCherry (U87dEGFR-mCherry), as well as U87dEGFR cells not expressing any FP and 
serving as controls, were placed (in small capillary tubes) into the esophagus of a euthanized 
mouse, and the fluorescence was measured in transillumination geometry. The cells in the 
esophagus were located 8 mm away from the dorsal side and 4 mm from the ventral side, and 
the mouse was imaged in transillumination twice, once for each direction (dorsal to ventral 
and ventral to dorsal), in order to have two different location geometries of the cells. The 
recorded signals are presented in Fig. 3(c) and are normalized for the laser power, filter 
transmittance, and camera integration time. mCherry exhibited superior performance since the 
detected intensities were 7-200 times brighter than GFP. Signal intensity, however, was 
variable and depended on two factors: a) the excitation and emission wavelengths, i.e. the 
longer the wavelength, the lower the attenuation of signals from the tissue; and b) the location 
of the fluorescence activity, i.e. when the mCherry-expressing cells were closer to the 
illumination source the signal became stronger. The latter can be attributed to the higher tissue 
absorption at the excitation compared to the emission wavelength, and consequently, for a 
given total tissue thickness (in this case 12 mm), the shorter the excitation path, the brighter 
the signal. The GFP signal was independent of the location since the optical properties for the 
excitation and the emission wavelengths are similar (Fig. 3(c)). 
 
Fig. 3. Characteristic fluorescence and autofluorescence emission curves in deep tissue 
imaging. (a) In vivo relative spectral attenuation of light transmitted through 8 mm thick mouse 
tissue (upper left torso). Arrows indicate key wavelengths: blue – GFP excitation at 488 nm, 
green – GFP emission at 514 nm, orange – RFP excitation at 593 nm, and red bars – RFP 
emission 610-650 nm. The red arrow indicates the laser wavelength used for the calculation of 
the n-Born ratio. (b) normalized absorption and emission spectra for GFP and mCherry,   
(c) Normalized fluorescence of 10
6 U87dEGFR glioblastoma cells expressing FPs from deep 
tissue in transillumination mode. The orange shaded area indicates the intensity range of 
mCherry emission. The mCherry RFP emission was significantly higher when cells were closer 
to the excitation source (orange triangles pointing upward), than when they were closer to the 
detector (orange triangles pointing downward). GFP emission (cyan square) was essentially 
independent from the position. Black squares and lines indicate the autofluorescence intensity 
(control cells) and green squares and triangles show the emission of mCherry when excited at 
532 nm. Data were normalized for relative FP brightness. (d) In vivo normalized 
autofluorescence emission in transillumination of 12 mm thick mouse tissue (upper center 
torso) when excited at 6 different laser lines ranging from 488 - 750 nm (see color legend). The 
measurements were normalized for spectral window bandwidth, laser power, exposure time, 
i.e. units are photon counts.nm
1mW
1.s
1. The continuous lines are spline interpolations. 
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FP-expressing cells with the wild type glioblastoma cells. The most striking and unexpected 
finding was that autofluorescence increased for longer wavelengths (Fig. 3(c)). This finding is 
in direct contrast to the well-established notion that autofluorescence decreases with longer 
excitation and emission wavelengths [33,34], but this is valid only for reflectance 
measurements. These findings were also verified by in vivo measurement of tissue 
autofluorescence in transillumination geometry, using a series of excitation and emission 
wavelengths (Fig. 3(d)). The reason that autofluorescence in transillumination geometry 
increases for longer excitation and emission wavelengths is that tissue absorption is lower at 
longer wavelengths (Fig. 3(a)). As a result, the propagating autofluorescence photons are 
more attenuated at shorter rather than at longer wavelengths. It appeared that the 
autofluorescence spectral profiles excited at 593 and at 532 nm were relatively similar. 
Finally, the autofluorescence excited at 593 nm (Fig. 3(c), black line) was also similar to the 
signal obtained for mCherry-expressing cells excited at 532 nm (Fig. 3(c), green line), far 
from the excitation peak. 
3.2. Tissue autofluorescence removal, multispectral normalized Born ratios, and signal 
reconstruction 
We took advantage of the similar autofluorescence profiles at 532 nm and 593 nm in order to 
subtract the autofluorescence from the raw fluorescence images. As an example, raw 
transillumination images from a single projection of a mouse’s head containing brain tumor 
expressing mCherry are presented in Fig. 4. In the fluorescence image depicted in Fig. 4(a), 
there was increased signal from the left side of the cranium (where the tumor was injected) 
but there was also additional signal emanating from both sides. The autofluorescence image 
(Fig. 4(b)) primarily contains this additional signal that was subtracted to produce an 
autofluorescence corrected image (Fig. 4(c)), in which the signal coming outside the tumor 
area was eliminated (see Fig. 4 Media 1 for all angular projections). 
 
Fig. 4. Autofluorescence subtraction and normalization of raw transillumination images from a 
mouse head (dorsal view) with tumor expressing mCherry. – (Media 1) (a) Fluorescence image 
fl U  at 620 nm when excited at 593 nm, (b), Autofluorescence image 
au U at 620 nm excited at 
532 nm, (c), Correction with autofluorescence subtraction 
fl au Ua U  , (d) Normalization 
image of the head of the mouse at 635 nm, (e) n-Born ratio 
n U  (cyan) overlaid on the 
reflectance image of the head (grayscale). (g) Autofluorescence corrected n-Born ratio
n U  
overlaid on the reflectance image. (f) and (h) Density plots of all the uncorrected and corrected 
measurements, respectively, when each fluorescence pixel value is plotted vs the corresponding 
normalization pixel value (arbitrary units). 
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measurements  fl U  should be divided with the corresponding transillumination measurements 
n U  acquired at the excitation wavelength to correct (or normalize) for the illumination and the 
tissue inhomogeneities. However, free space acquisition of the transillumination images  n U  at 
the excitation wavelength (593 nm) is problematic due to the high tissue absorption and the 
low signal-to-stray-light ratio in the free-space transillumination geometry. It is therefore 
unsuitable for normalization. We addressed this problem with the acquisition of an additional 
normalization image  n U  using a 635 nm diode laser instead. This wavelength falls in the 
middle of the fluorescence acquisition range (610-650 nm), and light attenuation from 8mm-
thick tissue is 400 times lower than 593 nm (Fig. 3(a)). We had also tested normalization with 
a 650 nm laser, but the results were not as good as with the 635 nm. The autofluorescence-
corrected and normalized images are calculated for all filter set combinations by the formula 
 
0 fl au
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n
Ua U
U
U
 
    (5) 
where the scaling parameter a. Ideally, a should be such that the virtual detector values do not 
become negative after subtraction. However, the autofluorescence photon spatial distribution 
as imaged at 532 nm excitation is very similar, but not identical, to the corresponding 
distribution when excited at 593 nm, mostly due to the mismatch of optical properties of 
tissue for the excitation path between these wavelengths. In order to accommodate for this 
difference in autofluorescence spatial distribution, we have empirically defined that when the 
value of a is such that 20% of the virtual detector values used in the reconstruction become 
negative then the autofluorescence is efficiently subtracted. The negative values are excluded 
from the reconstruction. The subtraction affects mostly the data with the lowest n-Born 
values, that are the less important for the reconstruction of the fluorescence. The 
autofluorescence excited by 635 nm is insignificant, and therefore it is not necessary to correct 
the normalization image. The normalized images  nB U  for  0 a   and for  1.0 a   (when 20% 
of  nB U  is negative) are presented in Fig. 4(e) and 4(g), respectively. In the corrected and 
normalized image (Fig. 4(c)), the maximum photon intensity is congruent to the anatomical 
position of the tumor implantation, while autofluorescence has been effectively eliminated. 
Finally, the distribution plots of the fluorescence intensity  fl U  versus normalization intensity 
n U  are plotted on a pixel-by-pixel basis for all angular projections in Figs. 4(f) and 4(h), for 
0 a   and  1.0 a  , respectively (see also video for all angular projections). It can be seen that 
the original pixel distribution (when  0 a  ) is unrealistically confined to a small area with 
high fluorescence values due to the unsubtracted background autofluorescence. However, 
after subtraction, the intensities are more evenly distributed occupying a larger dynamic 
range, which increases the diversity of the experimental data set and improves reconstruction. 
In order to tomographically reconstruct the fluorescence activity, the examined volume 
was discretized in a mesh grid of Nm mesh points. For every source-detector (s-d) 
combination, the contribution/weight of each mesh point m to the fluorescence intensity 
detected at d was calculated by modeling the photon propagation using the n-Born 
approximation [7]. Contrary to the almost constant optical properties of tissue in NIR, at 
which diffuse and fluorescence tomographies have been developed to work, the absorption 
coefficient changes dramatically in the 590-650 nm region (Fig. 3(a)), thus increasing the 
diversity of the multispectrally acquired data set. When these changes are incorporated in the 
forward light propagation model, the ill-posedness of the inverse problem is reduced and the 
solution is constrained [35–37]. We introduce a 3-wavelength n-Born ratio (Fig. 5(a)) where 
(a) light propagation from source to meshpoint is modeled using the optical properties of 
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multispectral wavelengths from 610 to 650 nm, and (c) light propagation from source to 
detector using the ones at 635 nm. The multispectral forward equation was assembled by 
stacking all single-spectral measurements and weight functions to create a multispectral 
weight matrix that was inverted to reconstruct the 3D distribution of the fluorescence activity. 
 
Fig. 5. Multispectral fluorescence tomography reconstruction. (a) Schematic of the 3-
wavelength n-Born ratio calculation. Here, s, m, and d are the source, mesh, and detector 
positions, respectively. Gsm, Gmd, and Gsd are the Green’s functions that model the 
corresponding propagating photon fields between s, m, and d. (b) Drawing of the cross section 
of the phantom containing 1% Intralipid and 1% whole blood. Small circles indicate the 
position of the two tubes containing 15 and 60 pmol of Texas Red fluorochrome. (c) A 3D 
view of the surface of the phantom with the positions of the sources (red crosses) and the 
detectors (blue circles) as projected on the surface. (d) Selected axial slices of the 3D single- 
and multi-spectral reconstructions of the fluorescence concentration (arbitrary units) of the two 
tubes inside the phantom. Black discs indicate the cross section of the phantom. (b) and (d) are 
on the same scale. 
The reconstruction algorithm was tested by imaging a tissue mimicking cylindrical agar 
phantom containing 1% Intralipid and 1% whole blood. Two tubes of 1 mm diameter, 
containing 60 and 15 pmol of TexasRed (Sigma-Aldrich), which has similar absorption and 
emission characteristics to the RFPs, were enclosed inside the phantom (Fig. 5(b)). The actual 
fluorescence intensity ratio of the straws as measured immediately before their insertion in the 
phantom was 3.7. In Fig. 5(d), a comparison of the reconstructed fluorescence distribution is 
presented, using the single-wavelength data sets separately and the combined multispectral 
data set and inversion. The multispectral reconstruction improved performance over the 
single-wavelength both in terms of accuracy in localizing the tubes and in quantization. The 
ratio of the fluorescence between the two tubes ranges between 4.6 and 5.9 (23-59% error) for 
the single-wavelength reconstructions, compared to 3.4 (8% error) for the multispectral. 
Finally, with the single spectral reconstructions the sizes (FWHM) of the reconstructed tubes 
ware ranging between 4.2 and 4.5 mm and 3-3.5 mm for the 60 and 15 pmol respectively, and 
with the multispectral reconstructions improved to 3 and 2.2 mm respectively. 
3.3. Fluorescence tomography of mCherry-expressing brain tumors in mice 
To test the performance of the fluorescent protein tomography in vivo, we employed a mouse 
brain-tumor model in which U87dEGFR human glioblastoma cells expressing mCherry were 
stereotactically implanted in the left brain hemisphere. Figure 6 depicts the results of the 
reconstructed fluorescent cells implanted at a depth 3.5 mm from dura. The surface of the 
head, the geometry of the sources (red) and the virtual detectors, as well as the location of a 
selected axial plane (slice 3) are depicted in Fig. 6(a). From the comparison of the 
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reconstruction improves localization and size accuracy and reduces artifacts. The accuracy of 
localization and size can be also verified by the fluorescence tomographic and comparative 
magnetic resonance (MR) images in Fig. 6(d) and 6(e), respectively. Overall, there was 
excellent congruence in the localization of the tumor activity when compared with MR or thin 
cryosection slices in all viewing directions. When we did not apply autofluorescence 
subtraction, the mCherry signal was still reconstructed in the correct place and head similar 
value, however there were also artifacts in the image. For changes of 10-20% to the scaling 
parameter  a  the morphology of the reconstructions and the values practically remained the 
same; the changes in the peak values were approx. 1-2%. The reason is that autofluorescence 
subtraction affects mostly the low normalized Born ratio values, which are mostly responsible 
for the artifacts The high performance of the reconstruction scheme is attributed to use of the 
autofluorescence subtraction, the multispectral reconstruction, and, above all, to the use of 
data acquired using 360-degrees angular projections. 
 
Fig. 6. Representative example of intracranial U87dEGFR-mCherry glioblastoma 
reconstruction. (a) A 3D view of the surface of the mouse’s head, sources (red crosses) and 
detectors (blue circles) are projected on the surface. The black rectangle indicates the position 
of the axial slice 3. (b) A fluorescence epi-illumination image of histological section (slice #3) 
of the brain, blue – reflectance image at 593 nm, magenta – mCherry fluorescence emission at 
620 nm when excited at 593 nm. (c) Single- and multi-spectral reconstructions of the mCherry 
fluorescence at the axial slice #3. (d) A series of axial slices of the mCherry tumor 
reconstructed fluorescence, and (e) Corresponding post-Gd-DTPA enhanced axial slices from 
the T1-weighted MRI series. Orange arrows indicate the position of the glioma. Colorbar for  
(c) and (d) is in arbitrary units. Dashed lines in (c) and (d) are visual guides to indicate the 
brain area. 
4. Conclusions 
According to model-based calculations [21], and measurements in this work, switching from 
GFP to the RFPs and utilizing optimum excitation wavelengths, yields an increase of over two 
orders of magnitude in the detected fluorescence emanating from deep-tissue. In addition, the 
recently developed IFP isolated from the bacteriophytochrome Deinococcus Radiodurans 
[20], is highly suitable for tomograpic imaging, since the excitation and emission peaks (684 
and 708 nm) fall in the lower plateau of the tissue absorption. According to a simple 
simulation (similar to Ref. [21].) of the intensity of the IFP signal emanating from deep tissue, 
the improvement over RFPs is expected to be another order of magnitude. Regarding the 
detection limit, the background to which the FP signals are compared, is not the intrinsic noise 
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major limiting factor. From this stance, the improvement in switching from GFP to RFPs and 
IFP in transillumination geometries is compromised, since at longer wavelengths, the 
autofluorescence increases in addition to the fluorescence (Fig. 3(d)). From the measurements 
in Fig. 3(c), the signal-to-autofluorescence ratio (SAR) is 5 for GFP and ranges between 1.5 
and 30 for mCherry depending on the wavelength and the location of the mCherry cells; 
according to simulations the SAR of IFP is expected to be equivalent to that of mCherry. The 
key-solution to increase the performance and to lower the detection limit of FMT is to 
effectively remove the autofluorescence using spectral subtraction/unmixing, either in the 
excitation or the emission wavelength domain. Technically, this is much easier to achieve 
with the RFPs and IFP, since the overall acquisition duration for multispectral data sets in the 
red and in the infrared part of the spectrum is a 2-3 orders of magnitude faster than the one in 
the visible. For bigger tumors the SAR would increase proportionally for both GFP and 
mCherry, affecting the detection limits of both proteins. Detection sensitivity is an important 
aspect, but accurate tomographic reconstruction is even more important. Free-space multiple-
projection data acquisition, which is critical for accurate reconstructions, is practically 
impossible bellow 600 nm, because the fidelity of the normalization images is compromised 
by stray light and the highly biased light transmission under the skin. 
In summary, we have combined multispectral 360-degrees sampling technologies and 
efficient autofluorescence subtraction schemes with the use of RFPs and we have 
demonstrated that the resulting tomographic modality is capable of reconstructing the 
fluorescence activity of RFPs with high spatial accuracy. We have used this system to image 
deep-seated brain tumors expressing the RFP mCherry, and found it to be congruent with 
corresponding MR imaging. Further efforts should be directed toward autofluorescence 
subtraction/unmixing that would be beneficial for the NIR tomographic imaging as well. The 
tomographic imaging of RFPs and IFPs in whole-body scale can reveal functional information 
that is otherwise invisible. Improvements in these techniques will accelerate discoveries 
associated with functional genomics, stem cell research and systems biology. 
Acknowledgments 
We thank Claudio Vinegoni, Jason Gaglia, Diane Mathis, and Christophe Benoist for many 
helpful discussions and Jenny Chan for the MR imaging. The research was supported by the 
National Institutes of Health grants R01EB004382, P50CA86355, U24CA092782 and a Marie 
Curie Intra-European Fellowship within the 7th European Community Framework 
Programme. 
 
#139767 - $15.00 USD Received 16 Dec 2010; revised 1 Mar 2011; accepted 7 Mar 2011; published 16 Mar 2011
(C) 2011 OSA 1 April 2011 / Vol. 2,  No. 4 / BIOMEDICAL OPTICS EXPRESS  900